科学家研发用于治疗年龄相关性黄斑变性的眼药水&#160有望取代注射治疗

2017-05-17 cnBeta cnBeta

年龄相关性黄斑变性 (AMD) 是一种导致老年人致盲的常见疾病，是一种可引起视力迅速丧失的视网膜退行性病变。患者每月需要用注射液进行治疗。据外媒报道，现在伯明翰大学的科学家团队开发了一种突破性的新治疗方法，用简单的眼药水可取代此前的注射液。据悉，仅在英国，AMD 就影响了超过 60 万人。而在美国，这种疾病是 50 岁以上人群失明的最常见原因之一。目前的治疗包括直接将药物注射至眼球内。这

年龄相关性黄斑变性 (AMD) 是一种导致老年人致盲的常见疾病，是一种可引起视力迅速丧失的视网膜退行性病变。患者每月需要用注射液进行治疗。据外媒报道，现在伯明翰大学的科学家团队开发了一种突破性的新治疗方法，用简单的眼药水可取代此前的注射液。

据悉，仅在英国，AMD 就影响了超过 60 万人。而在美国，这种疾病是 50 岁以上人群失明的最常见原因之一。目前的治疗包括直接将药物注射至眼球内。这些注射不仅有损伤眼睛的危险，还令患者非常痛苦。

值得庆幸的是，伯明翰大学的科学家团队开发了这种全新的治疗方法。该小组研发了一种细胞穿透肽（CPP），可以在数分钟内将药物带到眼睛的相关部位。研究人员使用 CPP 方法将有效和无毒的 AMD 治疗药物滴入到小鼠、大鼠和猪的眼睛中。这种眼药水的生物活性被证明与任何其他可替代的药物相当。

参与这项研究的 Felicity de Cogan 博士表示：“CPP 药物可能通过改变给药选项对 AMD 治疗产生重大影响。与目前的治疗相比，通过眼药水可以有效地自行管理药物，并能避免不利结果和使医疗成本显着降低。”(生物谷 Bioon.com)

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
2017-07-27 crystal0573

#眼药水#

39 0
[GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
2018-04-11 shenxlcyp

#相关性#

24 0
[GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
2017-10-27 lily1616

#年龄相关#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
2017-05-19 lqvr

#研发#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
2017-05-19 lingqf

#年龄相关性黄斑变性#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
2017-05-19 huangdf

#变性#

26 0
[GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
2017-05-19 muzishouyi

#黄斑#

23 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

医学知识

科学家研发用于治疗年龄相关性黄斑变性的眼药水&#160有望取代注射治疗

相关资讯

科室

工具

服务